Alejandra Negro

Medicine · Health Sciences

19h-index3.5kcitations74works26.42yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatocellular Carcinoma Treatment and Prognosis(40), Cancer Immunotherapy and Biomarkers(28), Liver Disease Diagnosis and Treatment(19), Pancreatic and Hepatic Oncology Research(13), Colorectal Cancer Treatments and Studies(8)

Publications74 total

Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial
RWTH Publications (RWTH Aachen)·2026Open Access
Figure S3 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
2025Open Access
Figure S1 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
2025Open Access
Figure S2 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
2025Open Access
Supplementary Data DS1 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
2025Open Access
Five-year overall survival (OS) and OS by baseline liver function from the Phase 3 HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Zeitschrift für Gastroenterologie·2025
Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC).
Journal of Clinical Oncology·2025· 9 cited
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
New England Journal of Medicine·2025· 135 cited
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial
Hepatology·2025· 8 citedOpen Access
Differential safety profiles of durvalumab monotherapy and durvalumab in combination with tremelimumab in adult patients with advanced cancers
Journal for ImmunoTherapy of Cancer·2025· 3 citedOpen Access
404: FIVE-YEAR OVERALL SURVIVAL (OS) AND OS BY BASELINE LIVER FUNCTION FROM THE PHASE 3 HIMALAYA STUDY OF TREMELIMUMAB (T) PLUS DURVALUMAB (D) IN UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC)
Gastroenterology·2025
Su1751: FIVE-YEAR OVERALL SURVIVAL (OS) AND OS BY TUMOR RESPONSE MEASURES FROM THE PHASE 3 HIMALAYA STUDY OF TREMELIMUMAB PLUS DURVALUMAB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC)
Gastroenterology·2025
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC
Journal of Hepatology·2025· 68 cited
Five-year overall survival (OS) and OS by tumour response measures from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Zeitschrift für Gastroenterologie·2025
127O Five-year overall survival (OS) and OS by baseline liver function from the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Annals of Oncology·2024· 4 citedOpen Access
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Journal of Hepatology·2024· 27 citedOpen Access
167P Non-viral aetiology subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Annals of Oncology·2024· 2 citedOpen Access
169P Outcomes by comorbidities (CMs) with tremelimumab (T) and durvalumab (D) in the phase III HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)
Annals of Oncology·2024· 2 citedOpen Access
T cell receptor and immune gene expression pharmacodynamics for durvalumab monotherapy and in combination with tremelimumab or bevacizumab in unresectable hepatocellular carcinoma (uHCC).
Journal of Clinical Oncology·2024· 2 cited
Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma
Journal of Clinical Oncology·2024· 39 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Ghassan K. Abou‐Alfa(29), Robin Kate Kelley(27), Bruno Sangro(18), Masatoshi Kudo(15), John F. Kurland(15), George Lau(13), Philip He(12), Stephen L. Chan(11), Yoon‐Koo Kang(11), Ann‐Lii Cheng(11), Junji Furuse(10), Wattana Sukeepaisarnjaroen(10), Vincent C. Tam(10), Nathan Standifer(10), Enrico N. De Toni(9), Lorenza Rimassa(9), María Reig(9), Peter R. Galle(8), Charu Gupta(8), Xuyang Song(8)